JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

7.48 -0.93

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.41

Max

7.55

Põhinäitajad

By Trading Economics

Sissetulek

3M

12M

Müük

21M

76M

P/E

Sektori keskmine

12.312

67.147

Kasumimarginaal

15.633

Töötajad

179

EBITDA

13M

27M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-33.42% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

24M

382M

Eelmine avamishind

8.41

Eelmine sulgemishind

7.48

Uudiste sentiment

By Acuity

100%

0%

337 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. apr 2026, 23:33 UTC

Kuumad aktsiad

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28. apr 2026, 23:24 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28. apr 2026, 22:46 UTC

Tulu

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28. apr 2026, 22:37 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28. apr 2026, 22:15 UTC

Tulu
Uudisväärsed sündmused

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28. apr 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28. apr 2026, 23:31 UTC

Tulu

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28. apr 2026, 23:30 UTC

Tulu

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28. apr 2026, 23:19 UTC

Market Talk
Tulu

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28. apr 2026, 23:09 UTC

Tulu

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28. apr 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees One Rate Rise to 4% in Benign Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28. apr 2026, 23:01 UTC

Uudisväärsed sündmused

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28. apr 2026, 22:51 UTC

Tulu

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28. apr 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. apr 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28. apr 2026, 22:40 UTC

Market Talk
Uudisväärsed sündmused

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28. apr 2026, 22:32 UTC

Tulu

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28. apr 2026, 22:22 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28. apr 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28. apr 2026, 22:14 UTC

Tulu

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28. apr 2026, 22:07 UTC

Market Talk
Uudisväärsed sündmused

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-33.42% langus

12 kuu keskmine prognoos

Keskmine 5 USD  -33.42%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

337 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat